Haleon plc launches £330 million share buyback

Haleon plc (LSE/NYSE: HLN), a leading consumer health company with a market capitalization of $44.68 billion, has announced the commencement of a share buyback program today, with plans to repurchase up to £330 million of its ordinary shares. This move follows the company’s previous announcement on February 27, 2025, regarding its share buyback intentions for 2025, and the completion of an off-market purchase of shares from Pfizer Inc. (NYSE:PFE) on March 18, 2025. According to InvestingPro data, management has been consistently executing share buybacks, contributing to the stock’s impressive 19.84% return over the past year.

The buyback program aims to return value to shareholders and is expected to positively impact the company’s earnings per share, which currently stands at $0.20. The initial tranche, worth up to £200 million, will begin immediately and is scheduled to conclude by June 26, 2025. Shares bought under this tranche will be canceled to reduce the company’s share capital. The company maintains a healthy dividend yield of 2.3%, demonstrating its commitment to shareholder returns.

Haleon has engaged Goldman Sachs International to execute the buyback on the London Stock Exchange (LON:LSEG). Goldman Sachs will operate independently from Haleon, particularly regarding the timing of purchases, even during closed periods.

The buyback is authorized under the shareholder approval obtained at Haleon’s Annual General Meeting on May 8, 2024. The company intends to seek further approval for share buybacks at the upcoming Annual General Meeting in May 2025.

The buyback program will be conducted within set parameters, adhering to the UK’s Market Abuse Regulation, Commission Delegated Regulation, and the UK Financial Conduct Authority’s Listing Rules.

Haleon, known for brands such as Advil, Sensodyne, and Centrum, is dedicated to improving everyday health through its wide range of consumer health products. This share buyback program is a part of the company’s broader strategy to enhance shareholder returns and demonstrates its confidence in the ongoing value of its business operations.

This report is based on the information provided in a press release statement.

In other recent news, Haleon plc has completed an off-market share repurchase, canceling 44,155,844 ordinary shares previously held by Pfizer Inc., with the transaction valued at approximately $170 million. This buyback is part of a broader £500 million repurchase plan for 2025, initially disclosed in February. The completion of this transaction marks Pfizer’s exit from Haleon’s shareholder base, reducing its stake from about 7.3% to zero. Additionally, Haleon announced the publication of its 2024 Annual Report and Form 20-F, providing a detailed overview of its financial performance. The report is accessible on Haleon’s website and through the National Storage Mechanism. Haleon also disclosed the granting of conditional share awards to its top executives, including CEO Brian McNamara, under various performance and bonus plans. These awards are tied to specific performance conditions to be assessed by the end of 2027. The company has emphasized its commitment to transparency in executive remuneration practices through these filings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.